Next generation kinase inhibitors
with unique properties

Potent and selective Nanocyclix leads for known

and novel kinases.

 

New partnering opportunity:  Nanocyclix RIPK2 inhibitors

for use in auto-immune diseases

 

READ MORE

Our ambition

Pave the way for a truly personalized approach in cancer.

 

 READ MORE

Translational biomarker approaches
to address patient needs

Pharmaco-imaging in support of therapeutic development

and for drug targeting.

 

 

READ MORE

State-of-the-art models for optimal
predictive value

Patient-derived xenografts and human immune system

models to allow better decisions.

 

 

READ MORE

We partner to advance cancer
research

Joining forces to the benefits of patients.

December 17, 2014
Oncodesign seals a major research agreement with Eisai in earlier line metastatic breast cancer treatment
READ MORE
April 21-23, 2015
Dr. Jan Hoflack will present progress on the RIPK2 and SIK2 kinase targets at the 10th Drug Discovery Chemistry conference in San Diego, CA
READ MORE

ONCOLOGY TRANSLATIONAL

EXPERIMENTATION

A large panel of technological and scientific solutions for pharmacological qualification of your compounds : a unique oncology preclinical CRO

DISCOVERY PARTNERING

 

A platform-based approach for the discovery of novel chemical entities with therapeutic and diagnostic potential